Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Xiang

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
International Journal of Radiation Oncology, Biology, Physics|March 2, 2023
Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging TrialsClayton P Smith, Michael Xiang, Wesley R Armstrong, et al.
Genes & Cancer|December 25, 2012
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.
Clinical Lung Cancer|December 1, 2023
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II TrialCaressa Hui, Eleanor Brown, Samantha Wong, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2023
High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical TrialTing Martin Ma, Deborah J Wong, Wanxing Chai-Ho, et al.
European Urology Oncology|March 4, 2023
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission TomographyClayton P Smith, James A Proudfoot, Paul C Boutros, et al.
American Journal of Hematology|December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analysesJennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
Blood Advances|December 20, 2019
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylationAlexandra M Stevens, Michael Xiang, Lisa N Heppler, et al.
Blood|August 18, 2016
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agentMichael Xiang, Haesook Kim, Vincent T Ho, et al.
Cancer Discovery|October 19, 2020
<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase InhibitionMichael S Binkley, Young-Jun Jeon, Monica Nesselbush, et al.
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
International Journal of Radiation Oncology, Biology, Physics|March 2, 2023
Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging TrialsClayton P Smith, Michael Xiang, Wesley R Armstrong, et al.
Genes & Cancer|December 25, 2012
The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsErik A Nelson, Sarah R Walker, Michael Xiang, et al.
Clinical Lung Cancer|December 1, 2023
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II TrialCaressa Hui, Eleanor Brown, Samantha Wong, et al.
International Journal of Radiation Oncology, Biology, Physics|May 4, 2023
High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical TrialTing Martin Ma, Deborah J Wong, Wanxing Chai-Ho, et al.
European Urology Oncology|March 4, 2023
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission TomographyClayton P Smith, James A Proudfoot, Paul C Boutros, et al.
American Journal of Hematology|December 29, 2020
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analysesJennifer R Brown, Sarah R Walker, Lisa N Heppler, et al.
Blood Advances|December 20, 2019
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylationAlexandra M Stevens, Michael Xiang, Lisa N Heppler, et al.
Blood|August 18, 2016
Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agentMichael Xiang, Haesook Kim, Vincent T Ho, et al.
Cancer Discovery|October 19, 2020
<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase InhibitionMichael S Binkley, Young-Jun Jeon, Monica Nesselbush, et al.
European Urology|August 7, 2022
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)Ting Martin Ma, Fang-I Chu, Howard Sandler, et al.
Pageof 7